Company Overview and News

0
Teranga Gold Schedules Second Quarter Conference Call and Webcast for August 2, 2018

2018-07-16 globenewswire
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) will release its second quarter 2018 financial and operating results on Thursday, August 2, 2018 at approximately 6:00 a.m. ET. A conference call and webcast hosted by management will follow at 8:30 a.m. ET to review the Company’s results and discuss the quarter’s highlights.
TGZ TGZ

0
Boss Resources enhances gold resource at West African prospects

2018-07-13 proactiveinvestors.com.au
Boss Resources Ltd (ASX:BOE) has hit near-surface and deeper gold intersections during drilling at three prospects within its Golden Hill property in Burkina Faso.
TGZ BOE TGZ

0
Teranga Gold’s Golden Hill Exploration Update Includes Strong Grades and Excellent Correlation at Multiple Prospects and a New Discovery at Peksou North

2018-07-12 globenewswire
TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that its most recent diamond drill program on the Golden Hill property in Burkina Faso, West Africa has returned near surface and deeper gold intersections that will enhance resources at a number of advanced prospects. In addition, the recent drilling evaluation program identified a new near-surface discovery at Peksou North, one of 9 prospects drilled at Golden Hill over the past 18 months.
TGZ BOE TGZ

19
U.S. Global's GO GOLD Gold Miners ETF Outperforms GDX And Sprott Gold Miners ETF In Its First Year

2018-07-02 seekingalpha
Last summer, U.S. Global Investors launched a new gold miners ETF, the U.S. Global GO GOLD and Precious Metal Miners ETF.
WPM GDX SGDM FSM SLW TGZ TGZ RGLD SLW GROW FNV RGL

2
Teranga Gold Increases Wahgnion’s M&I Resources 33% to 2.4 Million Ounces

2018-06-07 globenewswire
TORONTO, June 07, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce an updated mineral resource estimate for its Wahgnion gold development project (“Wahgnion”) in Burkina Faso, West Africa.
TGZ TGZ

12
Teranga Gold - I'm Still Bullish

2018-05-16 seekingalpha
In my opinion, the company is heading in the right direction: Sabodala performs well and the Wahgnion gold project in Burkina Faso is entering the development stage.
KGI KGI.DB.A RGORF KGI.DB EDVMF GRY GOLD RRS GPHYF GOLD TGZ TGZ EDVVF EVR KL EDV GSC

2
Teranga Gold Announces AGM Voting Results

2018-05-08 globenewswire
TORONTO, May 08, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) announces that all nominee directors listed in the Management Proxy Circular dated April 3, 2018 were elected as directors of the Company at its Annual General Meeting of Shareholders (the “Meeting”) held earlier today in Toronto, Ontario. At this Meeting, 69,914,888 shares were voted, representing 65.
TGZ TGZ

2
BRIEF-Teranga Gold Announces First Drawdown Under Facility For Construction Of Its Second Mine

2018-05-07 reuters
* TERANGA GOLD - FIRST DRAWDOWN UNDER PF TRANCHE WAS $70 MILLION, $15 MILLION OF WHICH USED TO CLOSE OUT REVOLVING CREDIT FACILITY WITH SOCIÉTÉ GÉNÉRALE
TGZ TGZ

2
Teranga Gold Announces First Drawdown Under Facility For Construction of its Second Mine

2018-05-07 globenewswire
TORONTO, May 07, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation (“Teranga” or the “Company”) (TSX:TGZ) (OTCQX:TGCDF) is pleased to announce that it has satisfied all conditions precedent for its first drawdown under the secured development finance facility with Taurus Funds Management Pty Ltd. (the “Facility”). The Facility is comprised of $165 million (the “PF Tranche”) to be used towards funding the development of the Wahgnion Gold Project (“Wahgnion”) and to repay all of the Company’s current outstanding bank debt totaling $15 million drawn on its revolving credit facility with Société Générale.
TGZ TGZ

2
Teranga Gold's (TGCDF) CEO Richard Young on Q1 2018 Results - Earnings Call Transcript

2018-05-05 seekingalpha
Good morning, and welcome to Teranga Gold Conference Call for the First Quarter and Year Ended March 31, 2018. As a reminder, this conference call is being recorded. Your host for today is Trish Moran, Head of Investor Relations. Ms. Moran, please go ahead.
TGZ TGZ

2
Teranga Gold Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-03 seekingalpha
The following slide deck was published by Teranga Gold Corporation in conjunction with their 2018 Q1 earnings call.
TGZ TGZ

2
BRIEF-Teranga Gold Posts Qtrly Earnings Per Share $0.03

2018-05-03 reuters
* TERANGA GOLD - OUTLOOK FOR SABODALA’S PRODUCTION IN 2018 IS 210,000-225,000 OUNCES OF GOLD Source text for Eikon: Further company coverage:
TGZ TGZ

2
Increased Production and Lower Costs Underpin Teranga Gold’s Q1 2018 Strong Operating Results

2018-05-03 globenewswire
TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- Teranga Gold Corporation ("Teranga" or the "Company") (TSX:TGZ) (OTCQX:TGCDF) today reported its financial and operating results for the three months ended March 31, 2018.
TGZ TGZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...